ProPhase Labs Inc
$ 0.15
-3.69%
23 Feb - close price
- Market Cap 757,920 USD
- Current Price $ 0.15
- High / Low $ 0.15 / 0.14
- Stock P/E N/A
- Book Value 1.65
- EPS -19.80
- Next Earning Report 2026-04-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -2.20 %
- 52 Week High 6.66
- 52 Week Low 0.12
About
ProPhase Labs, Inc. is engaged in the research, development, manufacture, distribution, marketing, and sale of consumer health products and over-the-counter (OTC) dietary supplements in the United States. The company is headquartered in Garden City, New York.
Analyst Target Price
$13.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-19 | 2025-08-13 | 2025-05-07 | 2025-03-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-15 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-28 |
| Reported EPS | -0.16 | -0.11 | -0.1328 | -1.59 | -0.35 | -0.33 | -0.07 | -0.51 | -0.3 | -0.2 | 0.03 | -0.12 |
| Estimated EPS | -0.11 | -0.15 | -0.18 | -0.24 | 0.04 | -0.24 | -0.28 | -0.26 | -0.19 | -0.14 | -0.09 | 0.03 |
| Surprise | -0.05 | 0.04 | 0.0472 | -1.35 | -0.39 | -0.09 | 0.21 | -0.25 | -0.11 | -0.06 | 0.12 | -0.15 |
| Surprise Percentage | -45.4545% | 26.6667% | 26.2222% | -562.5% | -975% | -37.5% | 75% | -96.1538% | -57.8947% | -42.8571% | 133.3333% | -500% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-01 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Previous Dividend Records
| Jun 2022 | Mar 2022 | Jan 1970 | Dec 2019 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|
| Payment Date | 2022-06-03 | 2022-03-10 | None | 2019-12-12 | None | None |
| Amount | $0.3 | $0.3 | $0.3 | $0.25 | $0.25 | $1.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRPH
2026-02-13 22:57:15
ProPhase Labs (PRPH) hosted an investor webinar on February 3, 2026, to highlight its high-growth healthcare assets and engage with investors. Despite a "Sell" rating and weak financial performance leading TipRanks' AI Analyst Spark to rate PRPH as "Neutral," the company seeks to strengthen investor understanding of its operations and growth prospects. Spark noted potential upside catalysts but acknowledged ongoing execution, liquidity, and dilution risks.
2026-02-03 12:00:00
ProPhase Labs (OTC: PRPH) is targeting significant liquidity events by initiating a potential sale or strategic partnership for its BE-Smart™ esophageal cancer test and advancing its Crown Medical Collections initiative for unpaid COVID-19 testing claims. The company believes BE-Smart™ has a large addressable market and aims to leverage a partner's infrastructure for broader adoption. Meanwhile, the Crown Medical initiative is showing strong recovery potential, particularly from underpaid commercial claims, and is attracting interest for recovery-based financing.
2026-02-03 11:58:15
ProPhase Labs announced it is exploring a potential sale or strategic partnership for its BE-Smart™ esophageal cancer test to generate liquidity and broaden its market reach. Simultaneously, the company is advancing its Crown Medical Collections initiative to recover unpaid COVID-19 diagnostic testing claims, noting that most outstanding claims are underpayments rather than outright denials, which strengthens the recovery profile. Both initiatives aim to provide significant liquidity, strengthen the company's balance sheet, and fund future growth.
2026-02-03 11:58:15
ProPhase Labs is pursuing a potential sale or strategic partnership for its BE-Smart™ esophageal cancer risk stratification test, which it estimates has a $14 billion annual addressable market. Concurrently, the company is advancing its Crown Medical Collections initiative to recover unpaid and underpaid COVID-19 diagnostic testing claims, noting that over 60% of these are underpaid rather than denied, potentially improving recovery prospects. Both initiatives are aimed at generating significant liquidity, strengthening the company's balance sheet, and transforming its financial outlook.
2026-02-03 07:00:15
ProPhase Labs is seeking a sale or strategic partnership for its BE-Smart™ esophageal cancer risk stratification test to generate liquidity and accelerate market penetration. Concurrently, the company is progressing its Crown Medical Collections initiative to recover unpaid COVID-19 diagnostic testing claims, noting that over 60% of these claims are underpayments, which strengthens the recovery potential and has attracted interest from financing sources. Both initiatives aim to significantly improve ProPhase Labs' financial position.
2026-02-03 06:29:15
ProPhase Labs is hosting an exclusive live investor webinar and Q&A session on February 3rd, featuring Chairman and CEO Ted Karkus. The event will showcase the company's high-growth healthcare assets, including its BE-Smart Esophageal Cancer Test and Nebula Genomics, highlighting recent milestones and future strategies. Investors will learn about ProPhase's efforts to unlock shareholder value through innovation and strategic growth.
